Triggered doxorubicin release in solid tumors from thermosensitive liposome‐peptide hybrids: Critical parameters and therapeutic efficacy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|3|731-743

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.3, 2015-08, pp. : 731-743

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liposome–nanoparticle hybrids for multimodal diagnostic and therapeutic applications

By Al-Jamal Wafa’ T   Kostarelos Kostas  

Nanomedicine, Vol. 2, Iss. 1, 2007-02 ,pp. : 85-98

Future Medicine

Access to resources Recommend Favorite

A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 190-196

Karger

Access to resources Recommend Favorite

Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 69, Iss. 3, 2005-10 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 463-469

Karger

Access to resources Recommend Favorite

Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 62, Iss. 3, 2002-06 ,pp. : 216-222

Karger

Access to resources Recommend Favorite